Mainz Biomed, a molecular genetics diagnostic company that specializes in the early detection of cancer, is proud to announce that ColoAlert®, their efficient and easy-to-use screening test for colorectal cancer (CRC), has been selected by three German-based companies for their corporate health programs. This decision is a testament to the reliability and efficacy of the test, and serves as a reminder of the importance of early cancer detection.
Mainz Biomed is proud to work with three new companies to ensure their employees have access to colorectal cancer screening. With nearly 73,000 cases of colorectal cancer diagnosed in Germany annually, early detection and diagnosis can make a huge difference in terms of treatment options and outcomes.
Through the incorporation of ColoAlert into corporate health programs, employees can easily receive the testing they need to stay healthy. We salute these companies for making employee health a priority!
Mainz Biomed is dedicated to helping its employees with the BGM program by providing the ColoAlert® test and confidential results through an easy-to-use online portal. Employees can opt to have their physician notified of their results, and Mainz Biomed provides education and guidance on CRC and next steps, making it easier than ever to stay on top of their health.
Mainz Biomed’s ColoAlert® is the perfect solution for colorectal cancer (CRC) screening from the comfort of your own home. This non-invasive test offers superior early detection than fecal occult blood tests (FOBT) by utilizing PCR-technology to analyze tumor DNA.
ColoAlert® is available in select EU countries through independent laboratories, corporate health programs, and direct sales. In the US, the product is currently undergoing evaluation in the FDA-registration trial ‘ReconAAsense’, and upon approval, Mainz Biomed plans to distribute it through regional and national laboratory service providers.
About Colorectal Cancer
Colorectal cancer is a major global health issue, with over 1.9 million new cases reported in 2020. Early detection is key, which is why the US Preventive Services Task Force recommends that individuals over 45 years of age should be screened with stool DNA tests like ColoAlert® every three years.
Despite this recommendation, roughly one-third of US residents aged 50-75 have never been screened for colon cancer. This gap in screening represents a massive $4.0B+ market opportunity in the US, with 16.6 million colonoscopies performed annually.
About Mainz Biomed NV
Mainz Biomed is revolutionizing the world of diagnostics with its market-ready molecular genetic solutions for life-threatening conditions. The Company’s flagship product, ColoAlert®, is a groundbreaking, non-invasive, and easy-to-use early-detection diagnostic test for colorectal cancer that uses real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.
This highly accurate test has already been successfully launched in Europe. Mainz Biomed is now running a pivotal FDA clinical study for US regulatory approval. Additionally, the Company has an early-stage product candidate on the horizon, PancAlert, which is also a pancreatic cancer screening test.